Celltrion to Evaluate Remsima (biosimilar, infliximab) Against COVID-19 in the UK

 Celltrion to Evaluate Remsima (biosimilar, infliximab) Against COVID-19 in the UK

Celltrion to Evaluate Remsima (biosimilar, infliximab) Against COVID-19 in UK

Shots:

  • Celltrion collaborates with the University of Oxford and University Hospitals Birmingham to study the efficacy of Remsima (CT-P13) as a potential treatment for COVID-19
  • UHB will test a series of new drugs in a CATALYST trial. If the CATALYST study indicates benefit CT-P13 it would then be assessed in larger-scale studies in one of the UK national platform trials RECOVERY or REMAP-CAP
  • Additionally, UHB will evaluate Izana Bioscience’s Namilumab (IZN-101) which is a mAb in a late-stage studies for RA and ankylosing spondylitis

Click here to read full press release/ article | Ref: UHB | Image: Brandbrander

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post